Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun;582(7813):492-494.
doi: 10.1038/d41586-020-01569-1.

Tumour metabolites hinder DNA repair

Comment

Tumour metabolites hinder DNA repair

Lei-Lei Chen et al. Nature. 2020 Jun.
No abstract available

Keywords: Cancer; Metabolism.

PubMed Disclaimer

Figures

Figure 1 |
Figure 1 |. How molecules in cancer cells inhibit the repair of DNA damage.
a, DNA wraps around histone proteins to form a structure called a nucleosome. In normal cells, the enzyme KDM4B catalyses the removal of methyl groups from the lysine 9 (K9) amino-acid residue of the protein histone 3 (H3) in the nucleosome. This H3K9 demethylation activity requires the small molecule α-ketoglutarate (α-KG). If a double-strand break in DNA occurs, H3K9 is methylated at the damage site and this local methylation signal recruits DNA-repair factors that include the proteins Tip60 and ATM. These fix the damage through a process called homology-dependent repair. b, As a result of certain mutations, some cancer cells accumulate small molecules termed oncometabolites that promote tumour growth. Sulkowski et al. have revealed a mechanism that underlies this phenomenon. Oncometabolites compete with α-KG for binding to KDM4B and thus inhibit the enzyme’s function. This results in H3K9 methylation across the genome. This global hypermethylation masks a local spike in H3K9 methylation occurring after DNA damage, and hinders the recruitment of DNA-repair factors. Unrepaired DNA damage can lead to genome instability and thus boost tumour growth.

Comment on

References

    1. Sulkowski PL et al. Nature 582, 586–591 (2020). - PMC - PubMed
    1. King A, Selak MA & Gottlieb E Oncogene 25, 4675–4682 (2006). - PubMed
    1. Ye D, Guan K-L & Xiong Y Trends Cancer 4, 151–165 (2018). - PMC - PubMed
    1. Rose NR, McDonough MA, King ONF, Kawamura A & Schofield CJ Chem. Soc. Rev 40, 4364–4397 (2011). - PubMed
    1. Chowdhury R et al. EMBO Rep. 12, 463–469 (2011). - PMC - PubMed